The Wnts are secreted cysteine-rich glycoproteins that have important roles in the developing embryo as well as in tissue homeostasis in adults. Dysregulation of Wnt signalling can lead to several types of cancer, including prostate cancer. A hallmark of the signalling pathway is the stabilization of the transcriptional co-activator β-catenin, which not only regulates expression of many genes implicated in cancer but is also an essential component of cadherin cell adhesion complexes. β-catenin regulates gene expression by binding members of the T-cell-specific transcription factor/lymphoid enhancer-binding factor 1 (TCF/LEF-1) family of transcription factors. In addition, β-catenin associates with the androgen receptor, a key regulator of prostate growth that drives prostate cancer progression. Wnt/β-catenin signalling can be controlled by secreted Wnt antagonists, many of which are downregulated in cancer. Activation of the Wnt/β-catenin pathway has effects on prostate cell proliferation, differentiation and the epithelial–mesenchymal transition, which is thought to regulate the invasive behaviour of tumour cells. However, whether targeting Wnt/β-catenin signalling is a good therapeutic option for prostate cancer remains unclear.
A hallmark of the Wnt signalling pathway is the stabilization of β-catenin, a transcription factor that regulates many genes implicated in cancer
Aberrant expression and localization of β-catenin in prostate cancer is more common than predicted by Wnt pathway mutations
Expression of Wnt and secreted Wnt antagonists is frequently altered in prostate cancer, the outcome of which is often inconsistent with the predicted effects of these proteins on β-catenin stability
Wnt/β-catenin and androgen receptor signals affect one another in several ways, and this crosstalk is likely to change during disease progression
Small-molecule inhibitors of Wnt/β-catenin signalling are anticipated to have therapeutic benefits, particularly for tumours driven by prostate cancer stem or progenitor cells
Several mouse models show promise for future studies of the role of Wnt/β-catenin signalling in prostate cancer and for preclinical tests of Wnt inhibitors
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Signal Transduction and Targeted Therapy Open Access 24 June 2022
Oncogene Open Access 28 March 2022
Cell Death & Disease Open Access 01 December 2021
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10–29 (2012).
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148–1159 (2008).
Pienta, K. J. & Bradley, D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 12, 1665–1671 (2006).
Takahashi, S. et al. Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. Proc. Natl Acad. Sci. USA 108, 4938–4943 (2011).
Uysal-Onganer, P. et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol. Cancer 9, 55 (2010).
Verras, M., Brown, J., Li, X., Nusse, R. & Sun, Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 64, 8860–8866 (2004).
Zhu, H. et al. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res. 64, 7918–7926 (2004).
Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469–480 (2006).
Lai, S. L., Chien, A. J. & Moon, R. T. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res. 19, 532–545 (2009).
MacDonald, B. T., Tamai, K. & He, X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9–26 (2009).
Giles, R. H., van Es, J. H. & Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653, 1–24 (2003).
Heuberger, J. & Birchmeier, W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb. Perspect. Biol. 2, a002915 (2010).
Takeichi, M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251, 1451–1455 (1991).
Rubinfeld, B. et al. Association of the APC gene product with β-catenin. Science 262, 1731–1734 (1993).
Su, L. K., Vogelstein, B. & Kinzler, K. W. Association of the APC tumor suppressor protein with catenins. Science 262, 1734–1737 (1993).
Oyama, T. et al. A truncated β-catenin disrupts the interaction between E-cadherin and α-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res. 54, 6282–6287 (1994).
Behrens, J. et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 382, 638–642 (1996).
Molenaar, M. et al. XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell 86, 391–399 (1996).
Voeller, H. J., Truica, C. I. & Gelmann, E. P. β-catenin mutations in human prostate cancer. Cancer Res. 58, 2520–2523 (1998).
Chesire, D. R., Ewing, C. M., Sauvageot, J., Bova, G. S. & Isaacs, W. B. Detection and analysis of β-catenin mutations in prostate cancer. Prostate 45, 323–334 (2000).
Gerstein, A. V. et al. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34, 9–16 (2002).
de la Taille, A. et al. β-Catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin. Cancer Res. 9, 1801–1807 (2003).
Wan, X. et al. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin. Cancer Res. 18, 726–736 (2012).
Yardy, G. W. et al. Mutations in the AXIN1 gene in advanced prostate cancer. Eur. Urol. 56, 486–494 (2009).
Jerónimo, C. et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 60, 753–766 (2011).
Chesire, D. R., Ewing, C. M., Gage, W. R. & Isaacs, W. B. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 21, 2679–2694 (2002).
Chen, G. et al. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101, 1345–1356 (2004).
Horvath, L. G. et al. Lower levels of nuclear β-catenin predict for a poorer prognosis in localized prostate cancer. Int. J. Cancer 113, 415–422 (2005).
Kallakury, B. V., Sheehan, C. E. & Ross, J. S. Co-downregulation of cell adhesion proteins α- and β-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum. Pathol. 32, 849–855 (2001).
Kallakury, B. V. et al. Decreased expression of catenins (α and β), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92, 2786–2795 (2001).
Whitaker, H. C. et al. Alterations in β-catenin expression and localization in prostate cancer. Prostate 68, 1196–1205 (2008).
Bismar, T. A., Humphrey, P. A., Grignon, D. J. & Wang, H. L. Expression of β-catenin in prostatic adenocarcinomas: a comparison with colorectal adenocarcinomas. Am. J. Clin. Pathol. 121, 557–563 (2004).
Chung, G. G., Kielhorn, E. P. & Rimm, D. L. Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray. Clin. Colorectal Cancer 1, 237–242 (2002).
Stambolic, V., Mak, T. W. & Woodgett, J. R. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 18, 6094–6103 (1999).
Mulholland, D. J., Dedhar, S., Wu, H. & Nelson, C. C. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene 25, 329–337 (2006).
Sharma, M., Chuang, W. W. & Sun, Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J. Biol. Chem. 277, 30935–30941 (2002).
Persad, S., Troussard, A. A., McPhee, T. R., Mulholland, D. J. & Dedhar, S. Tumor suppressor PTEN inhibits nuclear accumulation of β-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J. Cell. Biol. 153, 1161–1174 (2001).
Ng, S. S. et al. Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J. Biol. Chem. 284, 35308–35313 (2009).
Wappenschmidt, B. et al. PTEN mutations do not cause nuclear β-catenin accumulation in endometrial carcinomas. Hum. Pathol. 35, 1260–1265 (2004).
McManus, E. J. et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24, 1571–1583 (2005).
Ahmad, I. et al. β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 30, 178–189 (2011).
Voskas, D., Ling, L. S. & Woodgett, J. R. Does GSK-3 provide a shortcut for PI3K activation of Wnt signalling? F1000 Biol. Rep. 2, 82 (2010).
Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315 (2007).
Gharbi, S. I. et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404, 15–21 (2007).
Verheyen, E. M. & Gottardi, C. J. Regulation of Wnt/β-catenin signaling by protein kinases. Dev. Dyn. 239, 34–44 (2010).
Kim, N. H. et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal. 4, ra71 (2011).
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Gupta, S. et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 70, 6735–6745 (2010).
Bafico, A., Liu, G., Goldin, L., Harris, V. & Aaronson, S. A. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6, 497–506 (2004).
Schlange, T., Matsuda, Y., Lienhard, S., Huber, A. & Hynes, N. E. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 9, R63 (2007).
Thiele, S. et al. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J. Cell. Biochem. 112, 1593–1600 (2011).
Fiorentino, M. et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β-catenin in prostate cancer. Lab. Invest. 88, 1340–1348 (2008).
Resh, M. D. Targeting protein lipidation in disease. Trends Mol. Med. 18, 206–214 (2012).
Li, Z. G. et al. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27, 596–603 (2008).
Syed Khaja, A. S. et al. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS ONE 6, e26539 (2011).
Yamamoto, H. et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29, 2036–2046 (2010).
McDonald, S. L. & Silver, A. The opposing roles of Wnt-5a in cancer. Br. J. Cancer 101, 209–214 (2009).
Uysal-Onganer, P. & Kypta, R. M. Wnt11 in 2011—the regulation and function of a non-canonical Wnt. Acta Physiol. (Oxf.) 204, 52–64 (2012).
Li, X. et al. Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis. Oncogene 27, 7118–7130 (2008).
Liu, X. H. et al. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res. 67, 5747–5753 (2007).
Kawano, Y. & Kypta, R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116, 2627–2634 (2003).
Niehrs, C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25, 7469–7481 (2006).
Bovolenta, P., Esteve, P., Ruiz, J. M., Cisneros, E. & Lopez-Rios, J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J. Cell Sci. 121, 737–746 (2008).
Lodygin, D., Epanchintsev, A., Menssen, A., Diebold, J. & Hermeking, H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 65, 4218–4227 (2005).
Horvath, L. G. et al. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin. Cancer Res. 10, 615–625 (2004).
Wissmann, C. et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J. Pathol. 201, 204–212 (2003).
O'Hurley, G. et al. The role of secreted frizzled-related protein 2 expression in prostate cancer. Histopathology 59, 1240–1248 (2011).
Yee, D. S. et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol. Cancer 9, 162 (2010).
Hsieh, J. C. et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398, 431–436 (1999).
Ohigashi, T., Mizuno, R., Nakashima, J., Marumo, K. & Murai, M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 62, 61–68 (2005).
Horvath, L. G. et al. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate 67, 1081–1090 (2007).
Kawano, Y. et al. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer. Br. J. Cancer 100, 1165–1174 (2009).
Joesting, M. S. et al. Secreted frizzled related protein 1 is a paracrine modulator of epithelial branching morphogenesis, proliferation, and secretory gene expression in the prostate. Dev. Biol. 317, 161–173 (2008).
Joesting, M. S. et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 65, 10423–10430 (2005).
Hall, C. L., Daignault, S. D., Shah, R. B., Pienta, K. J. & Keller, E. T. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 68, 1396–1404 (2008).
Thudi, N. K. et al. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 71, 615–625 (2011).
Hall, C. L. et al. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res. 70, 9916–9926 (2010).
González-Sancho, J. M. et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer. Oncogene 24, 1098–1103 (2005).
Lonergan, P. E. & Tindall, D. J. Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 10, 20 (2011).
Truica, C. I., Byers, S. & Gelmann, E. P. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60, 4709–4713 (2000).
Yang, F. et al. Linking β-catenin to androgen-signaling pathway. J. Biol. Chem. 277, 11336–11344 (2002).
Pawlowski, J. E. et al. Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J. Biol. Chem. 277, 20702–20710 (2002).
Song, L. N. et al. β-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol. Cell. Biol. 23, 1674–1687 (2003).
Urbanucci, A., Waltering, K. K., Suikki, H. E., Helenius, M. A. & Visakorpi, T. Androgen regulation of the androgen receptor coregulators. BMC Cancer 8, 219 (2008).
Mulholland, D. J., Cheng, H., Reid, K., Rennie, P. S. & Nelson, C. C. The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J. Biol. Chem. 277, 17933–17943 (2002).
Yang, X. et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25, 3436–3444 (2006).
Li, Y. et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 69, 3332–3338 (2009).
Masiello, D. et al. Recruitment of β-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol. Endocrinol. 18, 2388–2401 (2004).
Amir, A. L. et al. A direct β-catenin-independent interaction between androgen receptor and T cell factor 4. J. Biol. Chem. 278, 30828–30834 (2003).
Beildeck, M. E., Gelmann, E. P. & Byers, S. W. Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway. Exp. Cell Res. 316, 1763–1772 (2010).
Mulholland, D. J., Dedhar, S., Coetzee, G. A. & Nelson, C. C. Interaction of nuclear receptors with the Wnt/β-catenin/Tcf signaling axis: Wnt you like to know? Endocr. Rev. 26, 898–915 (2005).
Yumoto, F. et al. Structural basis of coactivation of liver receptor homolog-1 by β-catenin. Proc. Natl Acad. Sci. USA 109, 143–148 (2012).
Chesire, D. R. & Isaacs, W. B. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene 21, 8453–8469 (2002).
Song, L. N. & Gelmann, E. P. Interaction of β-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J. Biol. Chem. 280, 37853–37867 (2005).
Mulholland, D. J., Read, J. T., Rennie, P. S., Cox, M. E. & Nelson, C. C. Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22, 5602–5613 (2003).
Li, H., Kim, J. H., Koh, S. S. & Stallcup, M. R. Synergistic effects of coactivators GRIP1 and β-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J. Biol. Chem. 279, 4212–4220 (2004).
Chen, S. Y. et al. Activation of β-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-β-catenin interaction. Mol. Cell. Biol. 26, 929–939 (2006).
Zhuo, M., Zhu, C., Sun, J., Weis, W. I. & Sun, Z. The β-catenin binding protein ICAT modulates androgen receptor activity. Mol. Endocrinol. 25, 1677–1688 (2011).
Koh, S. S. et al. Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and β-catenin with two different classes of DNA-binding transcriptional activators. J. Biol. Chem. 277, 26031–26035 (2002).
Labalette, C., Renard, C. A., Neuveut, C., Buendia, M. A. & Wei, Y. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and β-catenin. Mol. Cell. Biol. 24, 10689–10702 (2004).
Interactions with other proteins [online].
Liao, X., Thrasher, J. B., Holzbeierlein, J., Stanley, S. & Li, B. Glycogen synthase kinase-3β activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145, 2941–2949 (2004).
Mazor, M., Kawano, Y., Zhu, H., Waxman, J. & Kypta, R. M. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 23, 7882–7892 (2004).
Lucero, O. M., Dawson, D. W., Moon, R. T. & Chien, A. J. A re-evaluation of the “oncogenic” nature of Wnt/β-catenin signaling in melanoma and other cancers. Curr. Oncol. Rep. 12, 314–318 (2010).
Biechele, T. L. et al. Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci. Signal. 5, ra3 (2012).
Chien, A. J. et al. Activated Wnt/β-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl Acad. Sci. USA 106, 1193–1198 (2009).
Chesire, D. R., Dunn, T. A., Ewing, C. M., Luo, J. & Isaacs, W. B. Identification of aryl hydrocarbon receptor as a putative Wnt/β-catenin pathway target gene in prostate cancer cells. Cancer Res. 64, 2523–2533 (2004).
Nalesso, G. et al. WNT-3A modulates articular chondrocyte phenotype by activating both canonical and noncanonical pathways. J. Cell Biol. 193, 551–564 (2011).
Wang, G., Wang, J. & Sadar, M. D. Crosstalk between the androgen receptor and β-catenin in castrate-resistant prostate cancer. Cancer Res. 68, 9918–9927 (2008).
Gounari, F. et al. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21, 4099–4107 (2002).
Bierie, B. et al. Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22, 3875–3887 (2003).
Bruxvoort, K. J. et al. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res. 67, 2490–2496 (2007).
Pearson, H. B., Phesse, T. J. & Clarke, A. R. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 69, 94–101 (2009).
Yu, X. et al. Activation of β-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 69, 249–262 (2009).
Yu, X., Wang, Y., DeGraff, D. J., Wills, M. L. & Matusik, R. J. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30, 1868–1879 (2011).
Shahi, P. et al. Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS ONE 7, e30814 (2012).
Barker, N. & Clevers, H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5, 997–1014 (2006).
Watanabe, K. & Dai, X. Winning WNT: race to Wnt signaling inhibitors. Proc. Natl Acad. Sci. USA 108, 5929–5930 (2011).
Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5, 100–107 (2009).
Shan, J., Shi, D. L., Wang, J. & Zheng, J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44, 15495–15503 (2005).
Grandy, D. et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 284, 16256–16263 (2009).
Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620 (2009).
Thorne, C. A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat. Chem. Biol. 6, 829–836 (2010).
Gonsalves, F. C. et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl Acad. Sci. USA 108, 5954–5963 (2011).
Wang, W., Liu, H., Wang, S., Hao, X. & Li, L. A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis. Cell Res. 21, 730–740 (2011).
Lepourcelet, M. et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5, 91–102 (2004).
Ewan, K. et al. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res. 70, 5963–5973 (2010).
Emami, K. H. et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc. Natl Acad. Sci. USA 101, 12682–12687 (2004).
de la Roche, M. et al. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. Nat. Commun. 3, 680 (2012).
Lu, W. et al. Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation. Eur. J. Pharmacol. 602, 8–14 (2009).
Saleem, M. et al. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res. 65, 11203–11213 (2005).
Saleem, M. et al. Lupeol inhibits proliferation of human prostate cancer cells by targeting β-catenin signaling. Carcinogenesis 30, 808–817 (2009).
Siddique, H. R., Mishra, S. K., Karnes, R. J. & Saleem, M. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin. Cancer Res. 17, 5379–5391 (2011).
Jones, J. O. et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc. Natl Acad. Sci. USA 106, 7233–7238 (2009).
Chen, M. et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 48, 10267–10274 (2009).
Lu, W. et al. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. PLoS ONE 6, e29290 (2011).
Safety and efficacy study of PRI-724 in subjects with advanced solid tumors. ClinicalTrials.gov [online], (2012).
Phase I clinical study of CWP232291 in acute myeloid leukemia patients. ClinicalTrials.gov [online], (2012).
A study of oral LGK974 in patients with melanoma and lobular breast cancer. ClinicalTrials.gov [online], (2012).
Huang, L. et al. The role of Wnt5a in prostate gland development. Dev. Biol. 328, 188–199 (2009).
Wang, B. E., Wang, X. D., Ernst, J. A., Polakis, P. & Gao, W. Q. Regulation of epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt signaling. PLoS ONE 3, e2186 (2008).
Allgeier, S. H. et al. WNT5A selectively inhibits mouse ventral prostate development. Dev. Biol. 324, 10–17 (2008).
Ontiveros, C. S., Salm, S. N. & Wilson, E. L. Axin2 expression identifies progenitor cells in the murine prostate. Prostate 68, 1263–1272 (2008).
Wend, P., Holland, J. D., Ziebold, U. & Birchmeier, W. Wnt signaling in stem and cancer stem cells. Semin. Cell Dev. Biol. 21, 855–863 (2010).
Lukacs, R. U., Memarzadeh, S., Wu, H. & Witte, O. N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7, 682–693 (2010).
Taylor, R. A., Toivanen, R. & Risbridger, G. P. Stem cells in prostate cancer: treating the root of the problem. Endocr. Relat. Cancer 17, R273–285 (2010).
Bisson, I. & Prowse, D. M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 19, 683–697 (2009).
We thank Maria Vivanco (Center for Cooperative Research in Biosciences, CIC bioGUNE) for critical reading of the manuscript, and acknowledge support from the Spanish Ministry of Education and Science (grant SAF2011-30494), The Garfield Weston Foundation, The Dinwoodie Settlement and the Departments of Industry, Tourism and Trade (Etortek) and Innovation Technology of the Government of the Autonomous Community of the Basque Country.
The authors declare no competing financial interests.
About this article
Cite this article
Kypta, R., Waxman, J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol 9, 418–428 (2012). https://doi.org/10.1038/nrurol.2012.116
This article is cited by
Signal Transduction and Targeted Therapy (2022)
NEDD4L represses prostate cancer cell proliferation via modulating PHF8 through the ubiquitin–proteasome pathway
Clinical and Translational Oncology (2022)
MicroRNA-4429 suppresses proliferation of prostate cancer cells by targeting distal-less homeobox 1 and inactivating the Wnt/β-catenin pathway
BMC Urology (2021)
Cell Death & Disease (2021)